COMPASS Pathways, a mental health treatment firm, gained the designation for its psilocybin therapy for treatment-resistant depression in 2018. In 2019, Usona Institute, a nonprofit health-related researcher, gained the designation to carry on its screening of psilocybin like a treatment for signifi